LONDON – Medical inhaler company Vectura Group PLC (VEC.LN) Wednesday announced a collaboration with Sandoz, a division of Swiss drug giant Novartis AG (NVS), to develop a generic version of an inhaler therapy for asthma and chronic obstructive pulmonary disease.
Continue Reading Below
Vectura will receive an initial payment of $5 million from Sandoz and up to $5 million more depending on targets. It expects its research and development costs to be less than $20 million.
-Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
June 28, 2017 12:39 ET (16:39 GMT)